相似文献
1
The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation.
Cancer Immunol Immunother. 2009 Sep;58(9):1481-8. doi: 10.1007/s00262-009-0722-7. Epub 2009 May 23.
2
Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study.
Blood. 2002 Mar 15;99(6):1978-85. doi: 10.1182/blood.v99.6.1978.
3
Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Curr Opin Infect Dis. 2018 Aug;31(4):286-291. doi: 10.1097/QCO.0000000000000459.
4
Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.
Expert Rev Hematol. 2016 Nov;9(11):1093-1105. doi: 10.1080/17474086.2016.1242406. Epub 2016 Oct 11.
5
Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation.
Front Immunol. 2022 Sep 23;13:971156. doi: 10.3389/fimmu.2022.971156. eCollection 2022.
6
Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
Clin Microbiol Infect. 2015 Dec;21(12):1121.e9-15. doi: 10.1016/j.cmi.2015.06.009. Epub 2015 Jun 17.
7
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Lancet Infect Dis. 2019 Aug;19(8):e260-e272. doi: 10.1016/S1473-3099(19)30107-0. Epub 2019 May 29.
8
Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Transpl Infect Dis. 2008 Oct;10(5):325-32. doi: 10.1111/j.1399-3062.2008.00325.x. Epub 2008 Jul 8.
9
Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
Infez Med. 2012;20 Suppl 2:26-34.
10
Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.
Clin Transplant. 2019 Oct;33(10):e13666. doi: 10.1111/ctr.13666. Epub 2019 Aug 6.
引用本文的文献
1
Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review.
Pharmaceutics. 2024 Oct 11;16(10):1321. doi: 10.3390/pharmaceutics16101321.
2
Cyclophilin A as a target in the treatment of cytomegalovirus infections.
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618811413. doi: 10.1177/2040206618811413.
3
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.
Front Immunol. 2016 Nov 17;7:507. doi: 10.3389/fimmu.2016.00507. eCollection 2016.
4
Construction and Evaluation of Cytomegalovirus DNA Quantification System with Real-Time Detection Polymerase Chain Reaction.
Yonago Acta Med. 2016 Sep 12;59(3):217-222. eCollection 2016 Sep.
5
The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.
Cell Mol Life Sci. 2015 Nov;72(21):4049-62. doi: 10.1007/s00018-015-1986-z. Epub 2015 Jul 15.
6
Hematopoietic stem cell transplantation.
Stem Cells Cloning. 2010 Aug 26;3:105-17. doi: 10.2147/SCCAA.S6815.
7
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
Antimicrob Agents Chemother. 2013 Jul;57(7):3321-5. doi: 10.1128/AAC.00062-13. Epub 2013 May 6.
8
Antiviral drug resistance of human cytomegalovirus.
Clin Microbiol Rev. 2010 Oct;23(4):689-712. doi: 10.1128/CMR.00009-10.
本文引用的文献
1
Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.
J Immunol. 2011 Jul 1;187(1):7-9.
2
Artificial exosomes as tools for basic and clinical immunology.
J Immunol Methods. 2009 May 31;344(2):121-32. doi: 10.1016/j.jim.2009.03.011. Epub 2009 Apr 1.
3
Vaccine prevention of maternal cytomegalovirus infection.
N Engl J Med. 2009 Mar 19;360(12):1191-9. doi: 10.1056/NEJMoa0804749.
4
Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT.
Bone Marrow Transplant. 2009 Aug;44(3):185-92. doi: 10.1038/bmt.2008.435. Epub 2009 Jan 19.
5
Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT.
Bone Marrow Transplant. 2009 Jun;43(11):853-61. doi: 10.1038/bmt.2008.403. Epub 2008 Dec 22.
6
Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV.
Transplantation. 2008 Nov 27;86(10):1327-39. doi: 10.1097/TP.0b013e31818b6548.
7
Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation.
Blood. 2008 Nov 15;112(10):3974-81. doi: 10.1182/blood-2008-06-161695. Epub 2008 Sep 3.
8
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.
J Infect Dis. 2008 Jun 15;197(12):1634-42. doi: 10.1086/588385.
9
Novel inhibitors of human CMV.
Curr Opin Investig Drugs. 2008 Feb;9(2):132-45.
10
Human cytomegalovirus DNA replication: antiviral targets and drugs.
Rev Med Virol. 2008 May-Jun;18(3):177-210. doi: 10.1002/rmv.558.
Zotero 插件